Safety and Synergy of Capmatinib Plus Stereotactic Radiotherapy in MET Exon 14-Mutated Non-Small Cell Lung Cancer: A Case Report

Othmane Bensalah, Meryem Naciri, Mohamed Ali Boudraa, Fatimaezzahra Aouzah, Fadila Kouhen · 2025

Read Safety and Synergy of Capmatinib Plus Stereotactic Radiotherapy in MET Exon 14-Mutated Non-Small Cell Lung Cancer: A Case Report by Othmane Bensalah, Meryem Naciri, Mohamed Ali Boudraa, Fatimaezzahra Aouzah, Fadila Kouhen (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12822516.txt.

Description

Othmane Bensalah and co-authors report, in a 2025 case paper, a lung cancer paired care that held for two years. The man, 73, had a right top lung lump, chest node spread, bone spread, and a small brain spot. The tumor bore a MET exon 14 skip, a rare mark. Care mixed capmatinib, a drug that blocks MET, with pin-point rays to the bone spots and then the lung lump. The drug was held five days each side of each ray run. A bone guard drug rode as well.

No grave harm came. Scans showed the lumps shrink and hold; the brain spot cleared in full. At 24 months he lives with no spread seen. The pair was safe and strong in this case.

Catalog record

CREATOROthmane Bensalah, Meryem Naciri, Mohamed Ali Boudraa, Fatimaezzahra Aouzah, Fadila Kouhen
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE15 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12822516

Browse the full library · About the Tower of Babel